全文获取类型
收费全文 | 5832篇 |
免费 | 978篇 |
国内免费 | 112篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 305篇 |
妇产科学 | 81篇 |
基础医学 | 321篇 |
口腔科学 | 179篇 |
临床医学 | 417篇 |
内科学 | 1085篇 |
皮肤病学 | 132篇 |
神经病学 | 436篇 |
特种医学 | 101篇 |
外科学 | 593篇 |
综合类 | 496篇 |
预防医学 | 1008篇 |
眼科学 | 137篇 |
药学 | 200篇 |
10篇 | |
中国医学 | 42篇 |
肿瘤学 | 1324篇 |
出版年
2023年 | 156篇 |
2022年 | 112篇 |
2021年 | 253篇 |
2020年 | 330篇 |
2019年 | 263篇 |
2018年 | 283篇 |
2017年 | 290篇 |
2016年 | 280篇 |
2015年 | 250篇 |
2014年 | 407篇 |
2013年 | 459篇 |
2012年 | 350篇 |
2011年 | 327篇 |
2010年 | 261篇 |
2009年 | 241篇 |
2008年 | 251篇 |
2007年 | 252篇 |
2006年 | 265篇 |
2005年 | 212篇 |
2004年 | 207篇 |
2003年 | 183篇 |
2002年 | 172篇 |
2001年 | 143篇 |
2000年 | 100篇 |
1999年 | 77篇 |
1998年 | 60篇 |
1997年 | 69篇 |
1996年 | 58篇 |
1995年 | 55篇 |
1994年 | 66篇 |
1993年 | 51篇 |
1992年 | 55篇 |
1991年 | 44篇 |
1990年 | 34篇 |
1989年 | 41篇 |
1988年 | 37篇 |
1987年 | 21篇 |
1986年 | 26篇 |
1985年 | 32篇 |
1984年 | 26篇 |
1983年 | 20篇 |
1982年 | 22篇 |
1981年 | 17篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1976年 | 5篇 |
1974年 | 5篇 |
1972年 | 4篇 |
排序方式: 共有6922条查询结果,搜索用时 31 毫秒
1.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):94-103.e24
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established. 相似文献
2.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
3.
4.
目的:探讨应用GM(1,1)灰色模型在全国及分性别、地区的甲状腺癌发病率预测中的可行性,为制定措施预防甲状腺癌发病提供参考。方法:甲状腺癌发病数据来源于2008至2018年《中国肿瘤登记年报》,通过建立模型评价其预测效果并预测未来5年的发病率。结果:全国及分性别(男、女)、地区(城市、农村)甲状腺癌发病率预测模型分别为x^((1))(k+1)=37.5326e^(0.1152k)-33.2326(C=0.2083,P=1.00)、x^((1))(k+1)=15.6257e 0.1239k-13.6457(C=0.1969,P=1.00)、x^((1))(k+1)=59.7419e^(0.113k)-53.0619(C=0.2150,P=1.00)、x^((1))(k+1)=35.4451e ^(0.1408k)-30.2251(C=0.1519,P=1.00)、x^((1))(k+1)=16.7016e^(0.1294k)-15.0216(C=0.4918,P=1.00)。结论:GM(1,1)灰色预测模型可较好的拟合全国及分性别、城市的甲状腺癌发病率变化趋势并预测,对农村的拟合效果稍差。预测未来5年全国及分性别、地区甲状腺癌发病率将持续上升,提示应采取有针对性的措施加以预防。 相似文献
5.
目的 比较改良眶隔法和传统睑板法切开重睑术中的应用效果及对术后重睑形态、瘢痕发生率、角膜暴露率的影响。方法 选取2020年3月-2021年3月首都医疗爱育华医院收治的80例单睑患者,采用随机数字表法将其分对照组和观察组,各40例。对照组接受传统睑板法切开重睑术,观察组接受改良眶隔法切开重睑术,比较两组术后重睑形态、瘢痕发生率、角膜暴露率、并发症发生率。结果 观察组总有效率高于对照组,差异有统计学意义(P<0.05);观察组GAIS评分高于对照组,VAS评分低于对照组,差异有统计学意义(P<0.05);观察组右侧角膜暴露率增加值、左侧角膜暴露率增加值高于对照组,差异有统计学意义(P<0.05);观察组并发症发生率为5.00%,低于对照组的22.50%,差异有统计学意义(P<0.05)。结论 相比于传统睑板法切开重睑术,改良眶隔法切开重睑术不会过度增加术后角膜暴露率,术后瘢痕发生率更低,重睑形态更理想,患者接受度更高。 相似文献
6.
Idris Olasunmbo Ola Kirsi Talala Teuvo Tammela Kimmo Taari Teemu Murtola Paula Kujala Jani Raitanen Anssi Auvinen 《International journal of cancer. Journal international du cancer》2023,152(4):672-678
Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves overdetection of low-risk disease with potential adverse effects. We evaluated PCa incidence among men with PSA below 3 ng/mL and no PCa diagnosis at the first screening round of the Finnish Randomized Study of Screening for PCa. Follow-up started at the first screening attendance and ended at PCa diagnosis, emigration, death or the common closing date (December 2016), whichever came first. Cox regression analysis was used to estimate hazard ratios and their confidence intervals (CI). Among men with PSA <3 ng/mL, cumulative PCa incidence was 9.1% after 17.6 years median follow-up. Cumulative incidence was 3.6% among men with baseline PSA 0 to 0.99 ng/mL, 11.5% in those with PSA 1.0 to 1.99 ng/mL and 25.7% among men with PSA 2 to 2.99 ng/mL (hazard ratio 9.0, 95% CI: 7.9-10.2 for the latter). The differences by PSA level were most striking for low-risk disease based on Gleason score and EAU risk group. PSA values <1 ng/mL indicate a very low 20-year risk, while at PSA 2 to 2.99 ng/mL risks are materially higher, with 4- to 5-fold risk for aggressive disease. Using risk-stratification and appropriate rescreening intervals will reduce screening intensity and overdetection. Using cumulative incidence of clinically significant PCa (csPCa) as the criterion, rescreening intervals could range from approximately 3 years for men with initial PSA 2 to 2.99 ng/mL, 6 years for men with PSA 1 to 1.99 ng/mL to 10 years for men with PSA <1 ng/mL. 相似文献
7.
Qianlai Luo Jonathan N. Hofmann Ruth M. Pfeiffer Cari M. Kitahara Minkyo Song Meredith S. Shiels 《International journal of cancer. Journal international du cancer》2023,153(1):64-72
In the United States, renal cell carcinoma (RCC) incidence and the prevalence of obesity, an established risk factor for RCC, have been increasing for several decades. RCC is more common among older individuals. We sought to quantify the contribution of excess adiposity to the rising incidence of RCC among individuals 60 years or older. National Institutes of Health-American Association of Retired Persons Diet and Health Study data (n = 453 859 participants, enrolled in 1995-1996, age at enrollment 50-71 years) were used to estimate multivariable-adjusted hazard ratios (HRs) for RCC across body mass index categories and HRs associated with smoking. Population attributable fractions (PAFs) were calculated using estimated HRs and annual overweight/obesity prevalence from the National Health Interview Survey (1985-2008). PAF estimates were combined with RCC incidence from Surveillance, Epidemiology and End Results-13 to calculate annual percent changes in RCC incidence attributable (and unrelated) to overweight/obesity. We found that between 1995 and 2018, among individuals aged 60 years and older, PAF for overweight/obesity increased from 18% to 29% for all RCCs. In comparison, the PAF for smoking declined from 12% to 9%. RCC incidence increased 1.8% per year (95% confidence interval [CI] 1.5%-2.1%) overall, while RCC incidence attributable to overweight/obesity increased 3.8% per year (95%CI 3.5%-4.2%) and RCC incidence unrelated to overweight/obesity increased 1.2% per year (95% CI 0.9%-1.4%). In conclusion, overweight/obesity appears to have contributed importantly to the rising incidence of RCC in the United States since the mid-1990s. Public health interventions focused on reducing overweight and obesity could help substantially in curbing this trend. 相似文献
8.
9.
10.
V. Papp A. Iljicsov C. Rajda M. Magyari N. Koch‐Henriksen T. Petersen G. Jakab I. Deme F. Nagy P. Imre Z. Lohner K. Kovcs A. J. Birks . Kves G. Rum Z. Nagy L. Kernyi L. Vcsei K. Bencsik Z. Jobbgy P. Diszeghy L. Horvth G. Galntai J. Kasza G. Molnr M. Sim M. Stori C. Rzsa P. cs T. Berki G. Lovas S. Komoly Z. Illes 《European journal of neurology》2020,27(2):308-317